Haitong Picks HDFC Bank, ICICI, Cipla, Sun Pharma as Top India Large Caps
2d ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
india-stockshaitong-securities
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Haitong International Securities issued a research note on 17 June 2026 naming its top large capitalization stock recommendations for the Indian equity market. The brokerage's selections are concentrated in the banking and pharmaceutical sectors, highlighting HDFC Bank Ltd, ICICI Bank Ltd, Cipla Ltd, and Sun Pharmaceutical Industries Ltd as preferred exposures. This call targets stable, high-quality names within a market that has delivered a 22% total return in USD terms over the preceding twelve months. The firm's strategy emphasizes earnings resilience amid global macroeconomic uncertainty and domestic policy continuity.
Global asset allocators are currently scrutinizing emerging market equities for durable growth as developed market indices trade near record valuations. The MSCI India Index commands a forward price-to-earnings ratio of approximately 24x, a 70% premium to the broader MSCI Emerging Markets Index. This premium necessitates a highly selective stock-picking approach to justify continued investment.
The last major sector-specific overweight call by a global broker on Indian banks occurred in October 2025 when Morgan Stanley highlighted financials as a key beneficiary of sustained credit growth. That call preceded a 15% outperformance by the Nifty Bank Index versus the Nifty 50 over the subsequent six months. The current macro backdrop features the Reserve Bank of India's policy rate at 5.15%, with inflation trending within the central bank's 2-6% target band, providing a stable environment for net interest margin expansion.
The catalyst for Haitong's focused recommendation is a confluence of strong domestic loan growth, stable asset quality, and defensive demand characteristics in pharmaceuticals. Banking sector credit growth has sustained a pace above 16% year-over-year, supported by strong retail and corporate borrowing. Pharmaceutical companies benefit from steady domestic formulation sales and a stabilizing US generics market, offering a hedge against potential cyclical volatility.
The recommended stocks represent a combined market capitalization exceeding $320 billion as of mid-June 2026. HDFC Bank holds the largest weight, with a market cap of approximately $185 billion. The four stocks have consistently delivered superior return metrics compared to the benchmark.
A comparison of key financial health indicators illustrates the selection criteria.
| Stock | Price-to-Earnings (FY27E) | Return on Equity (FY26) | 3-Year Earnings CAGR |
|---|---|---|---|
| HDFC Bank | 19.2x | 16.8% | 18.5% |
| ICICI Bank | 17.8x | 17.5% | 20.1% |
| Cipla | 24.5x | 15.2% | 12.0% |
| Sun Pharma | 26.1x | 14.9% | 10.5% |
| Nifty 50 Index | 22.7x | ~15.0% | ~14.0% |
The selected banking stocks trade at a discount to the index P/E while offering higher projected earnings growth. Their price-to-book ratios, at 2.9x for HDFC Bank and 2.5x for ICICI Bank, remain below their five-year historical averages of 3.2x and 2.8x, respectively. This valuation gap presents a relative value argument within an expensive market.
Haitong's overweight stance on private banks signals a preference for entities with strong deposit franchises, which are less sensitive to tight systemic liquidity. This positioning directly benefits HDFC Bank and ICICI Bank, which control over 30% of system deposits among private lenders. It implies a relative underweight on public sector banks and newer fintech-driven lenders, which may face funding cost pressures.
The pharmaceutical picks reflect a strategic defensive tilt. Cipla and Sun Pharma derive 40-45% of revenue from the stable domestic Indian market, insulating them from currency volatility and US pricing pressures. This sector selection suggests a cautious view on global cyclical sectors like industrials and commodities, which are more exposed to export demand and input cost inflation.
A key limitation of this concentrated call is its sensitivity to interest rate movements. An unexpected aggressive tightening cycle by the RBI could compress bank net interest margins and pressure valuations. the healthcare sector faces regulatory risk from potential drug price controls in India.
Positioning data from exchange filings shows foreign institutional investors were net sellers of Indian equities to the tune of $1.2 billion in May 2026, but turned net buyers in early June. This flow reversal coincided with increased broker optimism on select large caps. Active funds are likely rotating capital from expensive technology and consumer discretionary names into these perceived value-and-defensive hybrids.
The immediate catalyst for these sectors is the Q1 FY2027 earnings season, commencing in mid-July 2026. Market focus will be on bank net interest margins, guided by commentary from HDFC Bank and ICICI Bank, and on pharmaceutical companies' US generic pricing trends and pipeline updates from Cipla and Sun Pharma.
Key technical levels for the Nifty Bank Index include immediate support at 52,800, its 100-day moving average, and resistance at 55,200. A sustained break above 55,200 would confirm the bullish sector rotation thesis. For the Nifty Pharma Index, the 16,500 level represents a multi-month consolidation ceiling; a decisive move above it could trigger momentum inflows.
The next monetary policy committee decision from the Reserve Bank of India on 8 August 2026 is the primary macro event. Consensus expects a hold, but any shift in the stance from "withdrawal of accommodation" would significantly reprice banking stocks. Clarity on US FDA inspection schedules for Indian pharma facilities in Q3 2026 will also drive volatility for Cipla and Sun Pharma.
For retail investors, this research highlights a shift towards fundamental quality and sector resilience. The note signals that professional money is prioritizing companies with strong balance sheets and visible earnings streams over speculative growth stories. Retail portfolios overly concentrated in mid-cap or thematic stocks may consider rebalancing towards these large-cap anchors for stability. It is not a recommendation to buy indiscriminately but a framework for evaluating holdings based on institutional-grade criteria like deposit stability and domestic revenue share.
Haitong's dual-sector focus is more concentrated than peers like Goldman Sachs and UBS, which have recently published broader India strategy notes with 15-20 stock ideas across multiple sectors. In April 2026, CLSA also favored private banks but paired them with select automobile and infrastructure names rather than pharmaceuticals. The uniqueness lies in combining financials and pharma as a complementary pair—banks for domestic cyclical growth and pharma for global defensive income—suggesting a portfolio designed for a potential growth slowdown.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.